Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.

Edward GaneMan-Fung YuenDong Joon KimHenry Lik-Yuen ChanBernadette SurujballyVedran PavlovicSudip DasMiriam TriyatniRemi KazmaJoseph F GrippoSimon BuatoisAnnabelle Lemenuel-DiotBen-Fillippo KrippendorffHenrik MuellerYuchen ZhangHyung Joon KimApinya LeerapunTien Huey LimYoung Suk LimTawesak TanwandeeWon KimWendy ChengTsung-Hui HuCynthia Wat

Published in: Hepatology (Baltimore, Md.) (2021)

RO7062931 is safe and well tolerated at doses up to 4.0 mg/kg QW. Supradose-proportional exposure at doses of 3.0-4.0 mg/kg was indicative of partial saturation of the ASGPR-mediated liver uptake system. Dose-dependent declines in HBsAg demonstrated target engagement with RO7062931.

Keyphrases

hepatitis b virus
social media
binding protein
clinical trial
double blind